CA2875281A1 - Methods of detecting single nucleotide polymorphisms at codon 600 of human braf - Google Patents
Methods of detecting single nucleotide polymorphisms at codon 600 of human braf Download PDFInfo
- Publication number
- CA2875281A1 CA2875281A1 CA2875281A CA2875281A CA2875281A1 CA 2875281 A1 CA2875281 A1 CA 2875281A1 CA 2875281 A CA2875281 A CA 2875281A CA 2875281 A CA2875281 A CA 2875281A CA 2875281 A1 CA2875281 A1 CA 2875281A1
- Authority
- CA
- Canada
- Prior art keywords
- oligonucleotide
- primer
- seq
- terminus
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 248
- 239000002773 nucleotide Substances 0.000 title claims abstract description 247
- 238000000034 method Methods 0.000 title claims abstract description 151
- 108020004705 Codon Proteins 0.000 title claims description 59
- 102000054765 polymorphisms of proteins Human genes 0.000 title description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 238
- 230000003321 amplification Effects 0.000 claims description 245
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 245
- 150000007523 nucleic acids Chemical class 0.000 claims description 119
- 102000039446 nucleic acids Human genes 0.000 claims description 117
- 108020004707 nucleic acids Proteins 0.000 claims description 117
- 238000006243 chemical reaction Methods 0.000 claims description 113
- 230000035772 mutation Effects 0.000 claims description 106
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 91
- 238000001514 detection method Methods 0.000 claims description 62
- 150000001413 amino acids Chemical group 0.000 claims description 52
- 230000002441 reversible effect Effects 0.000 claims description 38
- 108020004999 messenger RNA Proteins 0.000 claims description 34
- 101150048834 braF gene Proteins 0.000 claims description 32
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 239000002299 complementary DNA Substances 0.000 claims description 23
- 238000009396 hybridization Methods 0.000 claims description 20
- 229930024421 Adenine Natural products 0.000 claims description 17
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 17
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 17
- 229960000643 adenine Drugs 0.000 claims description 17
- 239000004474 valine Substances 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 10
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 44
- 239000013615 primer Substances 0.000 description 350
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 94
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 91
- 239000000523 sample Substances 0.000 description 86
- 108020004414 DNA Proteins 0.000 description 68
- 102000053602 DNA Human genes 0.000 description 68
- 102200055464 rs113488022 Human genes 0.000 description 55
- 238000003752 polymerase chain reaction Methods 0.000 description 53
- 235000001014 amino acid Nutrition 0.000 description 46
- 108700028369 Alleles Proteins 0.000 description 37
- 102220197820 rs121913227 Human genes 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 30
- 230000000295 complement effect Effects 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 25
- 238000013461 design Methods 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 13
- 238000003753 real-time PCR Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- -1 DNA Chemical class 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 230000001351 cycling effect Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 102200055469 rs121913377 Human genes 0.000 description 7
- 230000004544 DNA amplification Effects 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 230000037439 somatic mutation Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000012807 PCR reagent Substances 0.000 description 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000008366 buffered solution Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005382 thermal cycling Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 101100381977 Homo sapiens BRAF gene Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003116 impacting effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RGNHAWFQWRAADF-UHFFFAOYSA-N 1-[4-[[4-(dimethylamino)phenyl]diazenyl]phenyl]pyrrole-2,5-dione Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N2C(C=CC2=O)=O)C=C1 RGNHAWFQWRAADF-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- JZODKRWQWUWGCD-UHFFFAOYSA-N 2,5-di-tert-butylbenzene-1,4-diol Chemical compound CC(C)(C)C1=CC(O)=C(C(C)(C)C)C=C1O JZODKRWQWUWGCD-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 229940102297 B-raf kinase inhibitor Drugs 0.000 description 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 description 1
- 229920001076 Cutan Polymers 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035603 Pleural mesothelioma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 101710183263 Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- 239000007825 activation reagent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 239000002774 b raf kinase inhibitor Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000007851 intersequence-specific PCR Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000007855 methylation-specific PCR Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000007856 miniprimer PCR Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000007861 thermal asymmetric interlaced PCR Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013066 thyroid gland cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/107—Modifications characterised by incorporating a peptide nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/161—A competitive reaction step
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2545/00—Reactions characterised by their quantitative nature
- C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
- C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261652827P | 2012-05-29 | 2012-05-29 | |
| US61/652,827 | 2012-05-29 | ||
| US13/840,142 US10077474B2 (en) | 2012-05-29 | 2013-03-15 | Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits |
| US13/840,142 | 2013-03-15 | ||
| PCT/US2013/042817 WO2013181125A2 (en) | 2012-05-29 | 2013-05-28 | Method of designing primers, method of detecting single nucleotide polymorphisms (snps), method of distinguishing snps, and related primers, detectable oligonucleotides, and kits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2875281A1 true CA2875281A1 (en) | 2013-12-05 |
Family
ID=49670689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2875281A Abandoned CA2875281A1 (en) | 2012-05-29 | 2013-05-28 | Methods of detecting single nucleotide polymorphisms at codon 600 of human braf |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10077474B2 (enExample) |
| EP (2) | EP2855708B1 (enExample) |
| JP (2) | JP6448534B2 (enExample) |
| AU (2) | AU2013267660B2 (enExample) |
| CA (1) | CA2875281A1 (enExample) |
| ES (1) | ES2751371T3 (enExample) |
| WO (1) | WO2013181125A2 (enExample) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104928355A (zh) * | 2014-03-19 | 2015-09-23 | 李跃 | 检测braf基因突变的方法及其试剂盒 |
| CN109715826A (zh) * | 2016-04-29 | 2019-05-03 | 威斯康星州立大学医学院 | 用于评估癌症的多重优化错配扩增（moma）实时pcr |
| US11773434B2 (en) | 2017-06-20 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free DNA |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11946101B2 (en) | 2015-05-11 | 2024-04-02 | Natera, Inc. | Methods and compositions for determining ploidy |
| US12020778B2 (en) | 2010-05-18 | 2024-06-25 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12100478B2 (en) | 2012-08-17 | 2024-09-24 | Natera, Inc. | Method for non-invasive prenatal testing using parental mosaicism data |
| US12110552B2 (en) | 2010-05-18 | 2024-10-08 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12146195B2 (en) | 2016-04-15 | 2024-11-19 | Natera, Inc. | Methods for lung cancer detection |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12203142B2 (en) | 2014-04-21 | 2025-01-21 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| US12260934B2 (en) | 2014-06-05 | 2025-03-25 | Natera, Inc. | Systems and methods for detection of aneuploidy |
| US12270073B2 (en) | 2010-05-18 | 2025-04-08 | Natera, Inc. | Methods for preparing a biological sample obtained from an individual for use in a genetic testing assay |
| US12305229B2 (en) | 2014-04-21 | 2025-05-20 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12410476B2 (en) | 2010-05-18 | 2025-09-09 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12460264B2 (en) | 2016-11-02 | 2025-11-04 | Natera, Inc. | Method of detecting tumour recurrence |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013159035A2 (en) | 2012-04-19 | 2013-10-24 | Medical College Of Wisconsin, Inc. | Highly sensitive surveillance using detection of cell free dna |
| US9868981B2 (en) | 2015-06-11 | 2018-01-16 | Bio-Rad Laboratories, Inc. | Amplification assay with a probe competitor |
| EP3397766B1 (en) * | 2015-12-31 | 2023-05-17 | Quest Diagnostics Investments LLC | Compositions and methods for screening mutations in thyroid cancer |
| CN105861689A (zh) * | 2016-05-06 | 2016-08-17 | 北京晋祺生物科技有限公司 | 一种cyp3a5*3的检测引物组合物、试剂盒及方法 |
| CN111373050A (zh) | 2017-06-20 | 2020-07-03 | 生物辐射实验室股份有限公司 | 用于遗传不稳定性的数字扩增试验 |
| WO2019099420A1 (en) * | 2017-11-15 | 2019-05-23 | Yan Wang | A method for detecting multiple dna mutations and copy number variations |
| BR112021013020A2 (pt) * | 2018-12-31 | 2021-09-14 | Abbott Molecular Inc. | Amplificação melhorada de ácidos nucleicos |
| KR102321902B1 (ko) * | 2019-01-11 | 2021-11-05 | 주식회사 진캐스트 | Braf 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 |
| KR20220069111A (ko) * | 2019-10-02 | 2022-05-26 | 러트거즈,더스테이트유니버시티오브뉴저지 | 희귀 서열 변이체를 검출하기 위한 검정 방법 및 키트 |
| AU2021264510A1 (en) * | 2020-04-28 | 2022-12-01 | Cepheid | Pseudo-complementary bases in genotyping and nucleic acid sequencing |
| JPWO2023013421A1 (enExample) * | 2021-08-03 | 2023-02-09 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| CA1202962A (en) | 1982-10-19 | 1986-04-08 | David P. Clifford | Substituted n-phenyl-n'-benzoyl ureas and their use as insecticides and acaricides |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US5310893A (en) | 1986-03-31 | 1994-05-10 | Hoffmann-La Roche Inc. | Method for HLA DP typing |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5604099A (en) | 1986-03-13 | 1997-02-18 | Hoffmann-La Roche Inc. | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US4851331A (en) | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
| US5693517A (en) | 1987-06-17 | 1997-12-02 | Roche Molecular Systems, Inc. | Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5561058A (en) | 1986-08-22 | 1996-10-01 | Hoffmann-La Roche Inc. | Methods for coupled high temperatures reverse transcription and polymerase chain reactions |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5639611A (en) | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
| US5137806A (en) | 1989-12-11 | 1992-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection of sequences in selected DNA molecules |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| JP2985446B2 (ja) | 1990-10-31 | 1999-11-29 | 東ソー株式会社 | 核酸の検出及び測定方法 |
| US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| EP0540997A1 (en) | 1991-11-05 | 1993-05-12 | F. Hoffmann-La Roche Ag | Methods and reagents for HLA class I DNA typing |
| EP0655090B1 (en) | 1992-04-27 | 2000-12-27 | The Trustees Of Dartmouth College | Detection of gene sequences in biological fluids |
| CA2126952C (en) | 1994-06-28 | 2010-12-14 | Sithian Pandian | Probe, kit, and method of amplification for increasing the sensitivity of nucleic acid hybridization assays |
| US6235480B1 (en) | 1998-03-13 | 2001-05-22 | Promega Corporation | Detection of nucleic acid hybrids |
| WO2003095645A1 (en) | 2002-05-09 | 2003-11-20 | New York University | Assay for melanogenesis |
| US20030211483A1 (en) | 2002-05-09 | 2003-11-13 | Schroeder Benjamin G. | Methods for the enrichment of low-abundance polynucleotides |
| WO2005027710A2 (en) | 2002-09-11 | 2005-03-31 | Sequenom, Inc. | Methods for identifying subjects at risk of melanoma and treatments thereof |
| WO2004029288A2 (en) | 2002-09-26 | 2004-04-08 | Novartis Ag | Pcr-based diagnostic method of detecting a mutation in the b-raf gene |
| JP4116856B2 (ja) | 2002-10-02 | 2008-07-09 | 富士フイルム株式会社 | １塩基多型の検出方法 |
| US20040121374A1 (en) | 2002-10-02 | 2004-06-24 | Yoshihide Iwaki | Method for detecting single nucleotide polymorphisms |
| US7250289B2 (en) | 2002-11-20 | 2007-07-31 | Affymetrix, Inc. | Methods of genetic analysis of mouse |
| US7378233B2 (en) | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
| JP5162133B2 (ja) | 2003-12-03 | 2013-03-13 | アボット・ラボラトリーズ | 二本鎖直鎖核酸プローブ及びその使用 |
| EP1541695A1 (en) | 2003-12-09 | 2005-06-15 | Nanogen Recognomics GmbH | Use of a mutation in the BRAF gene for the determination of the malignancy of melanoma cells |
| WO2005066346A1 (ja) | 2003-12-26 | 2005-07-21 | Takeshi Nagasaka | 核酸増幅用プライマー、核酸増幅用プライマーセット及びこれを用いた癌の検査方法 |
| ES2244308B1 (es) | 2004-01-21 | 2007-02-16 | Oryzon Genomics, S.A. | Metodo de diagnostico molecular y tratamiento en cancer colorrectal esporadico inestable. |
| US7442507B2 (en) | 2005-01-24 | 2008-10-28 | New York University School Of Medicine | Methods for detecting circulating mutant BRAF DNA |
| US20070020657A1 (en) | 2005-05-20 | 2007-01-25 | Grebe Stefan K | Methods for detecting circulating tumor cells |
| WO2007002433A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
| US10144970B2 (en) | 2005-07-13 | 2018-12-04 | University Of Utah Research Foundation | Methods and compositions related to a BRAF mutation and microsatellite stability |
| WO2007106534A2 (en) | 2006-03-14 | 2007-09-20 | Harbor-Ucla Research And Education Institute | Selective amplification of minority mutations using primer blocking high-affinity oligonucleotides |
| US7803543B2 (en) * | 2007-01-19 | 2010-09-28 | Chang Gung University | Methods and kits for the detection of nucleotide mutations using peptide nucleic acid as both PCR clamp and sensor probe |
| US9556491B2 (en) | 2007-02-26 | 2017-01-31 | John Wayne Cancer Institute | Utility of B-RAF DNA mutation in diagnosis and treatment of cancer |
| US20100173294A1 (en) | 2007-09-11 | 2010-07-08 | Roche Molecular Systems, Inc. | Diagnostic test for susceptibility to b-raf kinase inhibitors |
| US20110212991A1 (en) | 2007-09-11 | 2011-09-01 | Roche Molecular Systems, Inc. | Diagnostic Test for Susceptibility to B-RAF Kinase Inhibitors |
| EP2220503A1 (en) | 2007-11-30 | 2010-08-25 | Schering Corporation | Braf biomarkers |
| WO2010011884A2 (en) | 2008-07-25 | 2010-01-28 | University Of Florida Research Foundation, Inc. | Novel nucleic acid-based molecular probes |
| EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| CN101487051B (zh) | 2009-02-24 | 2011-07-20 | 广州益善生物技术有限公司 | Braf基因突变的检测探针、液相芯片及其检测方法 |
| CA2770716A1 (en) | 2009-08-11 | 2011-02-17 | Response Genetics, Inc. | Methods, primers, probes and kits useful for the detection of braf mutations |
| US8728763B2 (en) * | 2009-08-11 | 2014-05-20 | Response Genetics | Methods, primers, probes and kits useful for the detection of BRAF mutations |
| KR101825117B1 (ko) | 2010-02-01 | 2018-02-06 | 주식회사 파나진 | Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｂｒａｆ 돌연변이 검출 방법 및 키트 |
| CN102161990A (zh) | 2010-02-24 | 2011-08-24 | 北京雅康博生物科技有限公司 | 用于定量检测braf突变的试剂盒 |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| WO2011104694A2 (en) | 2010-02-26 | 2011-09-01 | GAMMAGENETICS Sàrl | Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes |
| WO2011119934A2 (en) | 2010-03-26 | 2011-09-29 | Mayo Foundation For Medical Education And Research | Methods and materials for detecting colorectal neoplasm |
| CN102234684B (zh) | 2010-04-23 | 2014-01-01 | 益善生物技术股份有限公司 | Braf基因突变检测特异性引物和液相芯片 |
| EP2426217A1 (en) | 2010-09-03 | 2012-03-07 | Centre National de la Recherche Scientifique (CNRS) | Analytical methods for cell free nucleic acids and applications |
-
2013
- 2013-03-15 US US13/840,142 patent/US10077474B2/en not_active Expired - Fee Related
- 2013-05-28 EP EP13798093.4A patent/EP2855708B1/en active Active
- 2013-05-28 AU AU2013267660A patent/AU2013267660B2/en not_active Ceased
- 2013-05-28 ES ES13798093T patent/ES2751371T3/es active Active
- 2013-05-28 CA CA2875281A patent/CA2875281A1/en not_active Abandoned
- 2013-05-28 JP JP2015515106A patent/JP6448534B2/ja not_active Expired - Fee Related
- 2013-05-28 EP EP19187147.4A patent/EP3604552A1/en not_active Withdrawn
- 2013-05-28 WO PCT/US2013/042817 patent/WO2013181125A2/en not_active Ceased
-
2018
- 2018-06-27 JP JP2018121829A patent/JP2018196379A/ja active Pending
- 2018-08-20 US US16/105,057 patent/US20190032133A1/en not_active Abandoned
- 2018-10-19 AU AU2018250508A patent/AU2018250508A1/en not_active Abandoned
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12410476B2 (en) | 2010-05-18 | 2025-09-09 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12270073B2 (en) | 2010-05-18 | 2025-04-08 | Natera, Inc. | Methods for preparing a biological sample obtained from an individual for use in a genetic testing assay |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12110552B2 (en) | 2010-05-18 | 2024-10-08 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12020778B2 (en) | 2010-05-18 | 2024-06-25 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12100478B2 (en) | 2012-08-17 | 2024-09-24 | Natera, Inc. | Method for non-invasive prenatal testing using parental mosaicism data |
| CN104928355A (zh) * | 2014-03-19 | 2015-09-23 | 李跃 | 检测braf基因突变的方法及其试剂盒 |
| US12203142B2 (en) | 2014-04-21 | 2025-01-21 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US12486542B2 (en) | 2014-04-21 | 2025-12-02 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US12305229B2 (en) | 2014-04-21 | 2025-05-20 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12260934B2 (en) | 2014-06-05 | 2025-03-25 | Natera, Inc. | Systems and methods for detection of aneuploidy |
| US11946101B2 (en) | 2015-05-11 | 2024-04-02 | Natera, Inc. | Methods and compositions for determining ploidy |
| US12146195B2 (en) | 2016-04-15 | 2024-11-19 | Natera, Inc. | Methods for lung cancer detection |
| CN109715826A (zh) * | 2016-04-29 | 2019-05-03 | 威斯康星州立大学医学院 | 用于评估癌症的多重优化错配扩增（moma）实时pcr |
| US12460264B2 (en) | 2016-11-02 | 2025-11-04 | Natera, Inc. | Method of detecting tumour recurrence |
| US11773434B2 (en) | 2017-06-20 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free DNA |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12385096B2 (en) | 2018-04-14 | 2025-08-12 | Natera, Inc. | Methods for cancer detection and monitoring |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2855708B1 (en) | 2019-07-24 |
| AU2018250508A1 (en) | 2018-11-15 |
| WO2013181125A2 (en) | 2013-12-05 |
| US10077474B2 (en) | 2018-09-18 |
| AU2013267660A1 (en) | 2015-01-22 |
| EP2855708A2 (en) | 2015-04-08 |
| JP2018196379A (ja) | 2018-12-13 |
| ES2751371T3 (es) | 2020-03-31 |
| US20190032133A1 (en) | 2019-01-31 |
| WO2013181125A9 (en) | 2014-07-17 |
| US20130323727A1 (en) | 2013-12-05 |
| JP6448534B2 (ja) | 2019-01-09 |
| EP2855708A4 (en) | 2016-01-20 |
| AU2013267660B2 (en) | 2018-07-19 |
| JP2015518727A (ja) | 2015-07-06 |
| EP3604552A1 (en) | 2020-02-05 |
| WO2013181125A3 (en) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10077474B2 (en) | Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits | |
| JP6652693B2 (ja) | ブロッキングオリゴヌクレオチドを用いたｄｎａ増幅の方法 | |
| US9909187B2 (en) | Detection of single nucleotide polymorphisms in human KRAS | |
| EP2971158B1 (en) | Detection of bisulfite converted nucleotide sequences | |
| WO2014150300A2 (en) | Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits | |
| WO2017201276A1 (en) | Methods of detecting a mutated gene by multiplex digital pcr | |
| CN104685070B (zh) | 检测braf和pi3k突变的方法 | |
| US9169518B2 (en) | Primer set for detecting EGFR exon 21 polymorphism and application thereof | |
| WO2012146251A1 (en) | Method for detecting mutations using a three primer system and differently melting amplicons |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180216 |
|
| FZDE | Discontinued |
Effective date: 20220705 |
|
| FZDE | Discontinued |
Effective date: 20220705 |